Details of the Drug

General Information of Drug (ID: DMW1OQ0)

Drug Name
Clobazam - Lundbeck
Synonyms
Clobazam; Chlorepin; Urbanyl; Frisium; Clorepin; Urbadan; 22316-47-8; Clobazamum; Onfi; LM-2717; HR 376; RU-4723; Clobazamum [INN-Latin]; LM 2717; H-4723; H 4723; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione; UNII-2MRO291B4U; 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; NSC 336279; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; CCRIS 7506; 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione; EINECS 244-908-7; BRN 0758410; Onfi
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Approved [1], [2]
Epilepsy 8A60-8A68 Approved [1], [2]
Therapeutic Class
Neurology Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 300.74
Topological Polar Surface Area (xlogp) 2.1
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 32 hours (an oral dose of 40 mg) [5]
Metabolism
The drug is metabolized via the liver [6]
Vd
The volume of distribution (Vd) of drug is 100 L [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.188 mg/mL [3]
Chemical Identifiers
Formula
C16H13ClN2O2
IUPAC Name
7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione
Canonical SMILES
CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
InChI
InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3
InChIKey
CXOXHMZGEKVPMT-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2789
ChEBI ID
CHEBI:31413
CAS Number
22316-47-8
DrugBank ID
DB00349
TTD ID
D0S9MC
VARIDT ID
DR01295
INTEDE ID
DR0342
ACDINA ID
D00137

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-1 (GABRA1) TT1MPAY GBRA1_HUMAN Antagonist [8]
GABA(A) receptor gamma-3 (GABRG3) TTEX6LM GBRG3_HUMAN Modulator [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [12]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [11]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Anxiety disorder
ICD Disease Classification 6B00-6B0Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
GABA(A) receptor alpha-1 (GABRA1) DTT GABRA1 9.57E-01 -0.12 -0.18
P-glycoprotein 1 (ABCB1) DTP P-GP 7.83E-01 4.69E-02 1.89E-01
Cytochrome P450 2C18 (CYP2C18) DME CYP2C18 7.90E-01 3.72E-02 2.95E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 5.79E-01 -1.30E-02 -9.78E-02
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.66E-01 9.19E-03 4.88E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.06E-01 -2.42E-02 -1.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Clobazam - Lundbeck (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Altered absorption of Clobazam - Lundbeck due to GI dynamics variation caused by Sodium bicarbonate. Acidosis [5C73] [61]
Arn-509 DMT81LZ Moderate Increased metabolism of Clobazam - Lundbeck caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [62]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Oliceridine. Acute pain [MG31] [63]
Emapalumab DMZG5WL Moderate Altered metabolism of Clobazam - Lundbeck due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [62]
Galantamine DMEO794 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Galantamine mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [64]
Donepezil DMIYG7Z Minor Decreased metabolism of Clobazam - Lundbeck caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [65]
Siltuximab DMGEATB Moderate Altered metabolism of Clobazam - Lundbeck due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [62]
Voriconazole DMAOL2S Moderate Decreased metabolism of Clobazam - Lundbeck caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [64]
Desipramine DMT2FDC Moderate Decreased metabolism of Clobazam - Lundbeck caused by Desipramine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [64]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Clobazam - Lundbeck caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [66]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Clobazam - Lundbeck caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [67]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Clobazam - Lundbeck caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [64]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Clobazam - Lundbeck caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [67]
Pexidartinib DMS2J0Z Moderate Decreased metabolism of Clobazam - Lundbeck caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [64]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Clobazam - Lundbeck caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [68]
Letrozole DMH07Y3 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Letrozole mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [64]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Clobazam - Lundbeck caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [69]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Dihydrocodeine. Chronic pain [MG30] [70]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Clobazam - Lundbeck and Olopatadine. Conjunctiva disorder [9A60] [71]
Drospirenone DM1A9W3 Moderate Increased metabolism of Clobazam - Lundbeck caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [72]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Clobazam - Lundbeck caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [72]
Norgestimate DMYP4XC Moderate Increased metabolism of Clobazam - Lundbeck caused by Norgestimate mediated induction of CYP450 enzyme. Contraceptive management [QA21] [73]
Propofol DMB4OLE Moderate Additive cardiorespiratory depression effects by the combination of Clobazam - Lundbeck and Propofol. Corneal disease [9A76-9A78] [74]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Alfentanil. Corneal disease [9A76-9A78] [63]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Remifentanil. Corneal disease [9A76-9A78] [63]
Dextromethorphan DMUDJZM Moderate Decreased metabolism of Clobazam - Lundbeck caused by Dextromethorphan mediated inhibition of CYP450 enzyme. Cough [MD12] [64]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Clobazam - Lundbeck caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [64]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Clobazam - Lundbeck caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [75]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Clobazam - Lundbeck and Ethanol. Cystitis [GC00] [76]
MK-8228 DMOB58Q Moderate Increased metabolism of Clobazam - Lundbeck caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [77]
Aprepitant DM053KT Moderate Decreased metabolism of Clobazam - Lundbeck caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [78]
Trimipramine DM1SC8M Moderate Decreased metabolism of Clobazam - Lundbeck caused by Trimipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [64]
Imipramine DM2NUH3 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Imipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [64]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Clobazam - Lundbeck caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [64]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Clobazam - Lundbeck caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [79]
Paroxetine DM5PVQE Moderate Decreased metabolism of Clobazam - Lundbeck caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [64]
Duloxetine DM9BI7M Moderate Decreased metabolism of Clobazam - Lundbeck caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [80]
OPC-34712 DMHG57U Major Decreased metabolism of Clobazam - Lundbeck caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [81]
Clomipramine DMINRKW Moderate Decreased metabolism of Clobazam - Lundbeck caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [64]
Doxepin DMPI98T Moderate Decreased metabolism of Clobazam - Lundbeck caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [64]
Maprotiline DMPWB7T Moderate Decreased metabolism of Clobazam - Lundbeck caused by Maprotiline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [64]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Clobazam - Lundbeck and Esketamine. Depression [6A70-6A7Z] [82]
SODIUM CITRATE DMHPD2Y Minor Altered absorption of Clobazam - Lundbeck due to GI dynamics variation caused by SODIUM CITRATE. Discovery agent [N.A.] [61]
Tetrabenazine DMYWQ0O Moderate Decreased metabolism of Clobazam - Lundbeck caused by Tetrabenazine mediated inhibition of CYP450 enzyme. Dissociative neurological symptom disorder [6B60] [64]
Fenfluramine DM0762O Moderate Decreased metabolism of Clobazam - Lundbeck caused by Fenfluramine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [62]
Mephenytoin DM5UGDK Moderate Increased metabolism of Clobazam - Lundbeck caused by Mephenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Cenobamate DMGOVHA Moderate Decreased metabolism of Clobazam - Lundbeck caused by Cenobamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [64]
Stiripentol DMMSDOY Moderate Decreased metabolism of Clobazam - Lundbeck caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [84]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Clobazam - Lundbeck caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Rufinamide DMWE60C Moderate Increased metabolism of Clobazam - Lundbeck caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [62]
Cannabidiol DM0659E Moderate Decreased metabolism of Clobazam - Lundbeck caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [85]
Timolol DM3NXRU Moderate Decreased metabolism of Clobazam - Lundbeck caused by Timolol mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [86]
Tolterodine DMSHPW8 Minor Decreased metabolism of Clobazam - Lundbeck caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [87]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Clobazam - Lundbeck caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [88]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Clobazam - Lundbeck caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [64]
Cimetidine DMH61ZB Moderate Decreased metabolism of Clobazam - Lundbeck caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [89]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Clobazam - Lundbeck and Brimonidine. Glaucoma [9C61] [90]
Digoxin DMQCTIH Moderate Increased plasma concentration of Clobazam - Lundbeck and Digoxin due to competitive binding of plasma proteins. Heart failure [BD10-BD1Z] [91]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [92]
Rifampin DMA8J1G Minor Increased metabolism of Clobazam - Lundbeck caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [93]
Delavirdine DM3NF5G Minor Decreased metabolism of Clobazam - Lundbeck caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [94]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [95]
Efavirenz DMC0GSJ Moderate Decreased metabolism of Clobazam - Lundbeck caused by Efavirenz mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Etravirine DMGV8QU Moderate Decreased metabolism of Clobazam - Lundbeck caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Didanosine DMI2QPE Minor Altered absorption of Clobazam - Lundbeck due to GI dynamics variation caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [61]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [95]
Ritonavir DMU764S Moderate Decreased metabolism of Clobazam - Lundbeck caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [96]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Clobazam - Lundbeck caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [64]
Probenecid DMMFWOJ Minor Decreased metabolism of Clobazam - Lundbeck caused by Probenecid. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [97]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Clobazam - Lundbeck caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [62]
Ethinyl estradiol DMODJ40 Moderate Increased metabolism of Clobazam - Lundbeck caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [73]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Clobazam - Lundbeck and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [98]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Clobazam - Lundbeck and Lasmiditan. Migraine [8A80] [99]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Clobazam - Lundbeck and Flibanserin. Mood disorder [6A60-6E23] [100]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Clobazam - Lundbeck and Thalidomide. Multiple myeloma [2A83] [101]
Rifabutin DM1YBHK Minor Increased metabolism of Clobazam - Lundbeck caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [93]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [64]
Nilotinib DM7HXWT Moderate Decreased metabolism of Clobazam - Lundbeck caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [102]
Imatinib DM7RJXL Moderate Decreased metabolism of Clobazam - Lundbeck caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [103]
Modafinil DMYILBE Moderate Decreased metabolism of Clobazam - Lundbeck caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [64]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Clobazam - Lundbeck and Droperidol. Nausea/vomiting [MD90] [104]
Prochlorperazine DM53SRA Moderate Decreased metabolism of Clobazam - Lundbeck caused by Prochlorperazine mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [64]
Promethazine DM6I5GR Moderate Decreased metabolism of Clobazam - Lundbeck caused by Promethazine mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [64]
Metoclopramide DMFA5MY Moderate Decreased metabolism of Clobazam - Lundbeck caused by Metoclopramide mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [64]
Teduglutide DMYOAKS Moderate Altered absorption of Clobazam - Lundbeck caused by Teduglutide. Neonatal malabsorption syndrome [KB89] [105]
Dexfenfluramine DMJ7YDS Moderate Decreased metabolism of Clobazam - Lundbeck caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [64]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Levomethadyl Acetate. Opioid use disorder [6C43] [70]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Clobazam - Lundbeck and Apraclonidine. Optic nerve disorder [9C40] [90]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Pentazocine. Pain [MG30-MG3Z] [63]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Dextropropoxyphene. Pain [MG30-MG3Z] [106]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Butorphanol. Pain [MG30-MG3Z] [63]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Oxymorphone. Pain [MG30-MG3Z] [63]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Levorphanol. Pain [MG30-MG3Z] [63]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Dezocine. Pain [MG30-MG3Z] [63]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Nalbuphine. Pain [MG30-MG3Z] [63]
Methamphetamine DMPM4SK Moderate Decreased metabolism of Clobazam - Lundbeck caused by Methamphetamine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [107]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Buprenorphine. Pain [MG30-MG3Z] [108]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Hydrocodone. Pain [MG30-MG3Z] [63]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Meperidine. Pain [MG30-MG3Z] [63]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Oxycodone. Pain [MG30-MG3Z] [63]
Abametapir DM2RX0I Moderate Decreased metabolism of Clobazam - Lundbeck caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [109]
Esomeprazole DM7BN0X Moderate Decreased metabolism of Clobazam - Lundbeck caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [64]
Lefamulin DME6G97 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [107]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [64]
Enzalutamide DMGL19D Moderate Increased metabolism of Clobazam - Lundbeck caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [110]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Clobazam - Lundbeck caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [111]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Clobazam - Lundbeck due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [62]
Ixekizumab DMXW92T Moderate Altered metabolism of Clobazam - Lundbeck due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [62]
Levomepromazine DMIKFEL Moderate Decreased metabolism of Clobazam - Lundbeck caused by Levomepromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [64]
Fluphenazine DMIT8LX Moderate Decreased metabolism of Clobazam - Lundbeck caused by Fluphenazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [64]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Clobazam - Lundbeck and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [112]
Tocilizumab DM7J6OR Moderate Altered metabolism of Clobazam - Lundbeck due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [62]
Canakinumab DM8HLO5 Moderate Altered metabolism of Clobazam - Lundbeck due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [62]
Rilonacept DMGLUQS Moderate Altered metabolism of Clobazam - Lundbeck due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [62]
Golimumab DMHZV7X Moderate Altered metabolism of Clobazam - Lundbeck due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [62]
Sarilumab DMOGNXY Moderate Altered metabolism of Clobazam - Lundbeck due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [62]
Thioridazine DM35M8J Major Decreased metabolism of Clobazam - Lundbeck caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [113]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Clobazam - Lundbeck caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [114]
Iloperidone DM6AUFY Moderate Decreased metabolism of Clobazam - Lundbeck caused by Iloperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [64]
Haloperidol DM96SE0 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Haloperidol mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [64]
Perphenazine DMA4MRX Moderate Decreased metabolism of Clobazam - Lundbeck caused by Perphenazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [64]
Chlorpromazine DMBGZI3 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Chlorpromazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [64]
Risperidone DMN6DXL Moderate Decreased metabolism of Clobazam - Lundbeck caused by Risperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [64]
Pimozide DMW83TP Moderate Decreased metabolism of Clobazam - Lundbeck caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [64]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Clobazam - Lundbeck and Fentanyl. Sensation disturbance [MB40] [63]
Armodafinil DMGB035 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [64]
Norethindrone DMTY169 Moderate Increased metabolism of Clobazam - Lundbeck caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [73]
Fostamatinib DM6AUHV Moderate Decreased clearance of Clobazam - Lundbeck due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [115]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Clobazam - Lundbeck and Tizanidine. Tonus and reflex abnormality [MB47] [116]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Clobazam - Lundbeck and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [112]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Clobazam - Lundbeck and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [112]
Chlorpheniramine DM5URA2 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Chlorpheniramine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [64]
Mexiletine DMCTE9R Moderate Decreased metabolism of Clobazam - Lundbeck caused by Mexiletine mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [64]
Propafenone DMPIBJK Moderate Decreased metabolism of Clobazam - Lundbeck caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [64]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Clobazam - Lundbeck caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [64]
⏷ Show the Full List of 135 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Clobazam 10 mg tablet 10 mg Oral Tablet Oral
Clobazam 20 mg tablet 20 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7149).
2 Drug information of Clobazam, 2008. eduDrugs.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
11 In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
12 A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 2004 Dec;26(8):530-4.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
23 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
24 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
25 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
26 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
27 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
28 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
29 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
30 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
31 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
32 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
33 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
34 Drugs that may have potential CYP2B6 interactions.
35 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
36 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
37 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
38 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
39 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
40 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
41 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
42 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
43 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
44 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
45 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
46 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
47 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
48 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
49 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
50 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
51 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
52 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
53 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
54 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
55 Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16.
56 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
57 Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAA receptor subunits gene expression in the amygdala. J Psychopharmacol. 2011Jan;25(1):87-96.
58 Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
59 Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
60 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
61 Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
62 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
63 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
64 Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
65 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
66 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
67 Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
68 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
69 Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
70 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
71 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
72 Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
73 Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
74 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
75 Cerner Multum, Inc. "Canadian Product Information.".
76 Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
77 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
78 Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57. [PMID: 10668858]
79 Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS "Coadministration of nefazodone and benzodiazepines: 2. a pharmacokinetic interaction study with triazolam." J Clin Psychopharmacol 15 (1995): 320-6. [PMID: 8830062]
80 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
81 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
82 Cerner Multum, Inc. "Australian Product Information.".
83 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
84 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
85 Product Information. Epidiolex (cannabidiol). Greenwich Biosciences Inc, Carlsbad, CA.
86 Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
87 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
88 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
89 Grigoleit HG, Hajdu P, Hundt HK, et al. "Pharmacokinetic aspects of the interaction between clobazam and cimetidine." Eur J Clin Pharmacol 25 (1983): 139-42. [PMID: 6617718]
90 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
91 Castillo-Ferrando JR, Garcia M, Carmona J "Digoxin levels and diazepam." Lancet 2 (1980): 368. [PMID: 6105500]
92 Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6. [PMID: 6140941]
93 Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796]
94 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
95 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
96 Greenblatt DJ, vonMoltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI "Alprazolam-ritonavir interaction: Implications for product labeling." Clin Pharmacol Ther 67 (2000): 335-41. [PMID: 10801241]
97 Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
98 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
99 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
100 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
101 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
102 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
103 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
104 Canadian Pharmacists Association.
105 Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
106 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
107 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
108 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
109 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
110 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
111 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
112 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
113 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
114 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
115 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
116 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.